Quoin publishes peer-reviewed QRX003 paper; pediatric Netherton case clear at 21 months

Quoin Pharmaceuticals, Ltd.

Peer-reviewed paper in Dermatology and Therapy, published online Oct 13, 2026, introduces QRX003 and reports Prof. Alan Irvine's pediatric compassionate-use case.
Pediatric Netherton patient on once-daily whole-body QRX003 improved IGA from 4 (severe) to 1 at six weeks and WI-NRS itch from 5 to 1.
By eight months IGA was 0 (clear) and WI-NRS 0; over 21 months mostly IGA 0, off antihistamines, glucocorticoids and antivirals, no treatment-related adverse events.
Phase 2/3 CL-QRX003-004 interim: 4 of 6 (66.7%) met primary IGA endpoint (p=0.0087 vs alpha 0.0215); full 20-patient enrollment targeted by end-2026, topline Q2 2027.
Case is first pediatric use of QRX003 and longest continuous exposure to date; authors caution single-patient observations require trial confirmation.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.